(Q33956422)

English

Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

prostatic hypertrophy

1 reference

based on heuristic

inferred from title

author name string

Roehrborn CG

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

1 December 2001

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

58

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

953-959

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Preclinical pharmacology of alpha1-adrenoceptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Alpha 1A-adrenoceptor-mediated contractile responses of the human vas deferens

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The pharmacological perspective: role for the sympathetic nervous system in micturition and sexual function

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901448-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0090-4295(01)01448-0

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33956422&oldid=2046667269"